Sarah Routh
Family · Asheboro, NCNPI 1619497682
Payments from drug & device makers
Across 490 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AbbVie$859
- AstraZeneca$688
- Boehringer Ingelheim$368
- Pfizer$355
- plus $4K from 46 others
What the payments were for
- Food & beverage$7,932100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$240
How this compares
$7,932 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $37,784 |
| FarxigaDapagliflozin Propanediol | 18 | $20,276 |
| JanuviaSitagliptin Phosphate | 13 | $19,361 |
| OzempicSemaglutide | 14 | $16,160 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $15,002 |
| VascepaIcosapent Ethyl | 22 | $13,228 |
| BelsomraSuvorexant | 15 | $9,661 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $9,650 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,225 |
| JardianceEmpagliflozin | 11 | $6,564 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,637 |
| Rosuvastatin Calcium | 143 | $2,104 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $1,972 |
| Omeprazole | 70 | $1,714 |
| Atorvastatin Calcium | 132 | $1,503 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $355 | $37,78441 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $688 | $35,27842 claims |
| MerckJanuvia, Belsomra | $300 | $29,02228 claims |
| Boehringer IngelheimStiolto Respimat, Jardiance | $368 | $16,21426 claims |
| Novo NordiskOzempic | $1,003 | $16,16014 claims |
| GSKTrelegy Ellipta | $280 | $7,22511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Asheboro
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.